Revascularization in HFrEF
compared with medical treatment (MT) [8] [9] [10] for patients with CAD and HFrEF, with CABG becoming the recommended strategy; however, other potential therapeutic options currently include percutaneous coronary interventions (PCIs) and intensified, evidence-based MT; moreover, single studies in the setting of HF have been underpowered to draw definite conclusions, ultimately contributing to the uncertainty of current recommendations on the optimal strategy for patients with CAD and HFrEF. 1, 3 We aimed to perform an analysis of the totality of evidence of both randomized and observational studies evaluating the impact on mortality of available treatment options (CABG, PCI, and MT) for patients with HFrEF and CAD.
Methods Data Sources and Search Strategy
The meta-analysis was performed according to the established methods recommended by the Cochrane guidelines 11 and in compliance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses statement for conducting systematic reviews and meta-analyses in healthcare interventions. 12 A systematic literature search of articles until July 5, 2016, was performed, using the medical databases MEDLINE, EMBASE, Google Scholar, Web of Science, and the Cochrane Controlled Trials Register, as well as congress proceedings from major cardiovascular societies (American College of Cardiology [ACC] , American Heart Association [AHA] Scientific Sessions, and European Society of Cardiology [ESC] Congress). Search terms according to the medical subjects headings included revascularization, impaired ejection fraction, LVEF, severe left ventricular dysfunction, reduced ejection fraction, heart failure, ischemic cardiomyopathy, percutaneous coronary intervention, coronary artery bypass grafting, and medical therapy. A bibliography search within landmark articles and guidelines of cardiac societies on the subject was additionally performed, and relevant articles were added. Relevant citations were screened at the title/abstract level and retrieved as full-text reports, where possible.
Study Design, Selection Criteria, and Outcome Measures
We designed the current meta-analysis to compare CABG, PCI, and MT treatment strategies for patients with ejection fraction ≤40%. All randomized or observational trials comparing at least 2 of the 3 treatment modalities against each other with a minimum follow-up of 12 months and reporting all-cause mortality were eligible for inclusion. No language or publication status restriction was imposed. Exclusion criteria were (1) <12 months of follow-up, (2) mortality not reported, and (3) single-arm study.
The primary clinical end point was mortality; secondary end points were myocardial infarction (MI), repeat revascularization (RR), and stroke. RR was considered to be any revascularization, including target vessel revascularization.
Data Abstraction and Quality Assessment
The most updated or inclusive data for each study were used for abstraction. Two independent investigators (D.D. and G.W.), who were not personally involved in any of the included trials, abstracted data from each report into prespecified forms. Data were abstracted according to the intention-to-treat principle, where possible. Internal validity was independently appraised by 2 investigators (D.D. and G.W.); divergences were resolved by discussion with a third investigator (E.P.N.). Bias assessment was performed based on the Cochrane Handbook recommendations. 11 Additional sensitivity analyses were conducted to account for different types of emerging bias.
Statistical Analyses
Presented data are time-to-event outcomes. For meta-analyses of these outcomes, the most appropriate statistic to use is the hazard ratio (HR), which takes into account both the number of events and the time to these events. HR and 95% confidence intervals (CIs) were derived from survival parameters in each study and used as summary statistics. Heterogeneity was assessed by the Cochran Q test, and statistical heterogeneity was summarized by the I 2 statistic, which quantifies the percent of variation in study results that is because of heterogeneity rather than to chance. 13 I 2 values >50% indicate substantial heterogeneity. Pooled HR for all outcomes were calculated using the more conservative DerSimonian and Laird random-effects model. 11, 14 To validate the overall analyses of the primary mortality outcome, 3 prespecified sensitivity analyses were performed, namely studies with matched patients only (either randomized or propensity score matched), studies comparing CABG against drug-eluting stent (DES)-PCI, and studies published in 2010 or later.
Statistical significance for the summary HRs was assumed at a 2-tailed P value <0.05. Comprehensive Meta-Analysis software, version 2 (Biostat, Englewood, NJ) was used for statistical analyses.
Results

Study Selection and Patient Populations
Article screening and selection is described in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart (Figure 1 ). Of 1108 articles retrieved from the primary searches using prespecified keywords, 879 were excluded for unmet inclusion criteria.
Twenty-one studies published between 1983 and July 2016 were finally included in the meta-analysis (Table 1) , of which 16 available as full-text reports. 10, 15, 16, [18] [19] [20] [21] [22] [23] [24] 26, [29] [30] [31] [32] [33] [34] [35] For the remaining 5 articles, data were abstracted from the study summaries. 8, 17, 25, 27, 28 Patient baseline characteristics are shown in Table 2 . Of a total of 16 191 patients (mean age 64 years, 79% male), 7335 underwent CABG, 4439 underwent PCI, and 4417 received MT. Three trials involving 1779 patients had a randomized design, and 6 observational studies involving 2611 patients used propensity score or case-control matching, contributing to a total of 4410 patients in randomized or matched groups. For articles reporting both crude and propensity scorematched populations (Yang et al 35 and Velazquez et al 34 ), these groups were included separately in the overall and sensitivity analyses. Median follow-up was 36 months. Only a minority of studies performed viability testing in over 50% of patients.
The risks of bias of the included randomized and observational studies are shown in Tables I and II in the Data Supplement, respectively. Overall, bias was low across randomized controlled trials and moderate in observational studies.
Mortality With CABG, PCI, or MT
Eight studies, of which 2 had a randomized design, 21, 31 involved 6896 patients and reported mortality with CABG compared with contemporary MT (Figure 2A) Figure 2C ). There was a statistically significant reduction in mortality with CABG compared with PCI; the respective mortality rates were 18.95% (920 of 4856 patients) and 24.45% 
Secondary End Points With CABG Versus PCI
Myocardial Infarction
Eight studies with a total of 5122 patients reported data on first or recurrent MI ( Figure 3A ). Treatment with CABG resulted in a statistically significant reduction in MI compared with PCI; rates were 2.11% (62 of 2938) and 4.26% (93 of 2184), respectively (HR, 0.50; 95% CI, 0.36-0.68; P<0.001; heterogeneity P=0.51; I 2 =0%).
Repeat Revascularization
Seven studies, involving 3886 patients, provided data on RR ( Figure 3B) . 20, 22, 23, 25, 28, 30, 33, 35 There was a statistically significant reduction in RR with CABG compared with PCI treatment; the respective rates were 5. 
CABG Versus PCI in Patients Stratified by Disease or Treatment Characteristics
We investigated whether CABG or PCI favored special patient populations or patients preferably treated with DESs in the PCI group.
Four studies, with a total of 987 patients, reported a prevalence of left main/proximal left anterior descending disease >50% in both groups ( Figure 4A ). Mortality was still significantly reduced with CABG versus PCI, with respective rates of 17.08% (103 of 603 patients) and 25.0% (96 of 384 patients; HR, 0.76; 95% CI, 0.59-0.98; P=0.03; heterogeneity P=0.96; I 2 =0%). Seven studies involving 2695 patients reported a prevalence of 3-vessel disease >50% in both groups ( Figure 4B) . 18, [21] [22] [23] 28, 33 The overall incidence of all-cause mortality did not differ significantly between the 2 revascularization strategies: 27.85% (379 of 1361) among patients undergoing CABG and 30.51% (407 of 1334) among patients 
Discussion
The present article, to the best of our knowledge, represents the largest evidence base comparing mortality outcome after surgical, percutaneous, or conservative treatment of HFrEF and CAD. The main findings of this analysis are that (1) revascularization with either CABG or PCI carried a significant improvement in long-term survival over MT, (2) CABG showed a significantly improved survival compared with PCI, that persisted among patients with left main/proximal left anterior descending disease and in studies conducted after the advent of DES, and (3) CABG compared with PCI was associated with a significant reduction in the risk of MI or need for RR, albeit with a numerically higher rate of stroke.
There are potential anatomic and functional reasons for the described different mortality rates among the investigated patients' cohorts. (1) A complete revascularization can be more frequently reached with CABG than with PCI 36 ; completeness of revascularization by removing the ischemic burden might be a pivotal driver of improved prognosis, in particular in high-risk patients with HF caused by ischemic CAD. Although in the last years advances have been made in MT, the results on clinical outcomes offered by a complete revascularization could not be equalized by the sole MT in the high-risk subset with HFrEF. (2) In HF patients, CAD tends to be more complex and diffuse, leading to higher need for RRs and MI rates after coronary stenting than with CABG. 37, 38 (3) CABG revascularization of prolonged epicardial segments versus PCI performed only on specific stenotic lesion can yield a better vessel patency due to often extensively diseased arteries in ischemic HF. (4) In HF patients with low cardiac reserve, it is conceivable that in-stent restenosis would be more negatively impacting in this group than in others without severe dysfunction. (5) Improved survival after CABG could be related to fewer lethal ventricular arrhythmias or to reverse remodeling. The risk of contrast-induced acute nephropathy after PCI is also increased in more complex patients with HFrEF, potentially contributing to higher mortality rates when compared with CABG. 39 Findings from early randomized trials comparing medical therapy to CABG for the treatment of stable angina cannot be automatically extrapolated to the care of CAD patients with HF because this is a specific population that was largely excluded from the early stable angina trials. 31 The only randomized trial specifically addressing HF patients is STICH (Surgical Treatment for Ischemic Heart Failure), with its recently published 10-year extended follow-up (STICHES). 32 For similar reasons, the randomized trials comparing PCI to CABG in CAD patients have failed to provide definite answers on patients with comorbid HF. Indeed, only ≈2% of patients enrolled in the SYNTAX trial (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) had LVEF <30%. 40 More recently, the National Heart, Lung, and Blood Institute (NHLBI)-sponsored FREEDOM trial (Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease) reported similar outcomes with PCI using DESs and CABG in patients with LVEF <40%, but only 32 patients (2.5%) were in this prespecified subgroup. 41 Thus, the available randomized data comparing PCI and CABG in patients with severe left ventricular dysfunction are insufficient.
Current guidelines from the American and European cardiac societies are not uniform with respect to the class and level of treatment recommendations for CAD patients with HFrEF. The ESC guidelines recommend CABG over PCI for patients with HFrEF and significant CAD in the 8, 10, 16, 21, 26, 27, 31, 32, 34 ; (B) percutaneous coronary intervention (PCI) vs MT 21, 27 ; and (C) CABG vs PCI. 15, [17] [18] [19] [20] [21] [22] [23] [24] [25] [27] [28] [29] [30] 33, 35 ASAN-MAIN indicates Asan Medical Center-Left Main Revascularization; AWESOME, Angina With Extremely Serious Operative Mortality Evaluation; CASS, Coronary Artery Surgery Study; CI, confidence interval; CREDO-Kyoto, Coronary Revascularization Demonstrating Outcome Study in Kyoto; IRIS-MAIN, Observational Study for Left Main Disease Treatment; REAL, Regional Registry of Coronary Angioplasties; REHEAT, Revascularization in Heart Failure Trial; and STICH, Surgical Treatment for Ischemic Heart Failure. Revascularization in HFrEF presence of angina or viable myocardium. 42 PCI receives IIb C strength of recommendations for patients unsuitable for surgery, who have viable myocardium or significant left main stenosis or 2/3-vessel disease. The American College of Cardiology Foundation (ACCF)/AHA guidelines take a more liberal approach, suggesting CABG or PCI in patients with left main or multivessel disease in the case of angina and suitable coronary anatomy. 3 However, for patients with severely impaired left ventricular function and significant CAD in the absence of angina, only CABG is recommended as an alternative to MT, even in the absence of myocardial viability (Class IIb; Level of Evidence B). 3 The discrepancy among international recommendations, stemming from the lack of evidence from adequately powered randomized trials, challenges physicians in choosing the optimal strategy. 1, 3, 42, 43 Our findings derived from a large-scale analysis agree with those from STICH, unequivocally supporting the revascularization option in this high-risk group of patients. Our data for the first time add comprehensive information on the efficacy of percutaneous revascularization versus medical therapy, providing evidence that revascularization, irrespective of modality, in this specific population has the potential to improve the patients' outcomes. Moreover, they further expand current evidence by investigating the comparison between surgical and percutaneous revascularization, with a consistent long-term survival benefit provided by the surgical revascularization strategy. According to our meta-analysis and to the results of the STICH trial, surgical revascularization should be regarded as the preferred revascularization modality in these high-risk patients, followed by percutaneous interventions. These results suggest that current international guidelines should upgrade CABG to receive a higher class of recommendation and a higher level of evidence over PCI or MT.
An interesting finding of our study is that a significant mortality reduction is observed not only for patients with a classical indication for surgical revascularization (left main disease or 3-vessel disease), but possibly for all patients with significant CAD and impaired left ventricular function.
The comparison of CABG and PCI in patients with HFrEF shows a significant survival benefit for CABG in the present analysis. The low heterogeneity and the narrow 95% CIs suggest consistency of the findings that remained statistically significant in the subanalyses of CABG versus PCI using DES and of the randomized/matched cohorts. The reduction in mortality, however, was numerically smaller for CABG versus PCI than for CABG versus MT, in line with the findings of the present article on the benefits of PCI over MT. In a subanalysis of secondary end points, we found significantly reduced risk for MI and RR in patients treated with CABG versus PCI. 20, [22] [23] [24] [25] 30, 33, 35 ; (B) repeat revascularization 20, 22, 23, 25, 28, 33, 35 ; and (C) stroke. 20 46 and subsequent metaanalyses 47 have suggested that intermediate-term mortality after interventional revascularization using modern stent systems is comparable to CABG, with a reduced risk of stroke but a higher need for RR. Revascularization guidelines 42, 43 have thus expanded PCI indications in stable coronary heart disease, leaving the sole CABG recommendation to complex coronary anatomy with high SYNTAX scores or diabetes mellitus. 41, 48 Our findings indicate that surgical revascularization in patients with HFrEF should be regarded as the preferred strategy, with significant survival benefits in patients with left main/proximal left anterior descending disease and a numeric but nonsignificant mortality reduction in patients with 3-vessel disease.
Another important finding of the present report is that the significant survival improvement with CABG over MT or PCI occurred in patients largely without previous viability testing. The indication for revascularization in patients with HFrEF is most often based on clinical symptoms, for example, angina or decompensation, in the presence of significant CAD. The relevance of myocardial viability testing to determine the benefit/risk ratio of revascularization remains uncertain, with only a minority of studies providing signal for possible benefit 49 and guidelines generally recommending it as a reasonable procedure. 1, 3 European guidelines clearly advise against revascularization with either CABG or PCI in patients who have neither angina nor viable myocardium. 1, 40 American guidelines instead take a differing approach, giving a IIb recommendation to CABG, Figure 4 . Individual and summary hazard ratios for mortality in studies comparing coronary artery bypass grafting (CABG) vs percutaneous coronary intervention (PCI) stratified by patient characteristics or treatment: (A) in patients with left main/proximal left anterior descending disease 17, 22, 25, 33 ; (B) in patients with 3-vessel disease 15, 18, 19, [21] [22] [23] 28, 33 ; and (C) in studies using drug-eluting stents in the PCI group. 15, 20, [22] [23] [24] 35 independent of viable myocardium. 3 The present meta-analysis of all available studies on the topic shows a clear survival benefit for revascularization techniques (CABG as well as PCI) compared with MT, largely independent of viability testing. Our results are thus in line with current recommendations from American guidelines with respect to this point and suggest a minor role of viability testing in CAD patients with HFrEF.
In conclusion, this large-scale article emphasizes in patients with HF and CAD the mortality benefits of revascularizations over medical therapy; these findings prompt an update of international guidelines, with higher class and evidence of recommendations assigned to surgical revascularizations to these high-risk patients.
Limitations
The availability of individual patient data would have improved the results of our meta-analysis, especially of potential subgroup analyses. Only few randomized controlled trials were available, with the majority of studies being observational. The observational design has the advantage of adhering to the real world, more appropriately reflecting current practice of unselected higher risk patients versus those derived from randomized trials. Nonetheless, many sensitivity analyses were performed, including those limited to patients randomized or well matched, and were consistent with the main findings, suggesting that the overall effect is justified.
Data on single treatments in the medical therapy group were available only in a minority of studies; therefore, precise description of the adherence to standard guidelines for medical therapy in this patient cohort is not possible. On the other hand, a sensitivity analysis done with the more contemporary studies only confirmed the overall results. Moreover, additional sensitivity analyses in studies using randomization or patient matching have been conducted, generating highly matched patients in terms of allocated MTs; the findings are directionally convergent and have consistent magnitude with the main findings. Caution should be prompted when interpreting subgroup analyses that should be regarded as exploratory, given the degree of variability in patient background characteristics.
Conclusions
This meta-analysis provides evidence that revascularization, irrespective of modality, compared with medical therapy, significantly improves survival and other outcomes in patients with ejection fraction ≤40% and significant CAD. CABG seems to be the most favorable option in this setting, although PCI may have its advantages in special patients and situations. Careful assessment of procedural risk and discussion of the optimal treatment strategy within a heart team is mandatory and recommended by current guidelines. Additional randomized trials will be necessary to further define the most beneficial treatment for these high-risk patients.
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